Recent large randomized controlled trials have shown the cardiovascular and renal benefits of mineralocorticoid receptor antagonists (MRA) in patients with CKD and type 2 DM19, and MRA was recently approved for the treatment of CKD with type 2 DM. The gene discussed is NR3C2; the disease is chronic kidney disease.